Full-Time
Software Engineer
Mobile Automation Testing
Posted on 5/9/2026
Stryker
10,001+ employees
Manufactures orthopedic and surgical medical devices
No salary listed
Noida, Uttar Pradesh, India
Hybrid
Hybrid role; on-site in Gurugram with occasional remote work.
 Software Engineering (2) |
|---|
| , |
- Bachelor's degree in Software Engineering/ Computer Science
- 2-4 years of product testing in a product development environment or equivalent environment.
- Knowhow of different types of applications in mobile space, Windows and web applications.
- Strong hands on experience in writing both manual and automation scripts for iOS based mobile applications and web applications(Expert in Appium, Swift)
- Perform functional, regression, and system testing for iOS mobile applications and web applications, design, develop, and execute manual and automation scripts using frameworks like Appium, Swift or other iOS automation frameworks with minimum supervision.
- Collaborate with product owners and developers to understand requirements and deliver quality, Utilize the requirements management systems (JAMA).
- Document, track, and ensure timely closure of defects.
- Contribute to test strategy, test planning, and process improvements.
- Ensure adherence to Agile during test execution.
- Support test reporting and status updates for stakeholders.
- Perform software verification executions, debug, and resolution of issues.
- Produce complete, concise, clear and technically correct work outputs.
- Report passed and failed requirements to the test team lead or program management.
- Support test reviews of various deliverables and be able to handle end to end feature testing and overall system testing.
- Experience with integrated development environments (IDE) for projects for writing mobile automation scripts, Strong proficiency in writing automation scripts using Apple frameworks & tools (Swift/SwiftUI, Appium).
- Hands-on experience in mobile app test execution, debugging, and defect management.
- Software Development Life Cycle processes, know-how of Application Lifecycle Management /Traceability tools
- ISTQB and standard Agile certifications like CSM, SaFe Agile, mobile testing related certifications.
- Advanced knowledge of software configuration/version control and bug tracking tools.
- Experience in a medical device or regulated product development environment, Software Development Life Cycle processes and in using Application Lifecycle Management /Traceability tools.
- Experience with regulatory and compliance standards applied to the SDLC (Software Development Life Cycle).Knowledge of automation/programming frameworks like Python, Squish etc.
- Familiarity with CI/CD pipelines in embedded development environments and using requirements management and test tools (e.g., Jama, DOORS).
- Travel Percentage: 10%
Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Kalamazoo, Michigan
Founded
1941
Simplify's Take
What believers are saying
- Robotic surgery leadership drives double-digit sales growth through 2025.
- India Trident II launch targets aging population's rising hip surgeries.
- Peripheral vascular expansion via IVL meets growing arterial disease demand.
What critics are saying
- Handala cyberattack on March 11 delays ortho supply chain 3-6 months.
- Zimmer Biomet Persona IQ erodes ortho share with real-time analytics.
- J&J Velys captures 25% more knee procedures from Mako in 6-12 months.
What makes Stryker unique
- Stryker holds 39.1% US market share in orthopedic product manufacturing.
- Trident II Acetabular System integrates Mako SmartRobotics for hip replacements.
- Amplitude Vascular Systems acquisition adds CO₂ IVL for peripheral arteries.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Stryker who can refer or advise you
Benefits
Medical & prescription plans
Supplemental health benefits
Flexible Spending accounts
Employee Assistance Program
Short-term & long-term disability
Tuition reimbursement
401(k) plan
Employee Stock Purchase Plan
Company News
Distalmotion targets ASC gynecology programs with new FDA filing Distalmotion has submitted a 510(k) application to the FDA seeking to expand the label of its Dexter robotic surgery system into additional gynecological indications, the company announced April 1. The filing covers sacrocolpopexy, sacrocervicopexy and endometriosis resection. Sacrocolpopexy and sacrocervicopexy are procedures used to treat pelvic…
Stryker Corporation has signed a definitive agreement to acquire Amplitude Vascular Systems, a Boston-based medical technology company developing next-generation intravascular lithotripsy technology for treating calcified peripheral arterial disease. Financial terms were not disclosed. AVS's technology uses pulsed CO₂-generated pressure waves delivered through a balloon catheter to fracture calcium deposits. The platform aims to enhance catheter deliverability, treatment speed and therapy efficiency. The acquisition will strengthen Stryker's peripheral vascular portfolio and expand its presence in arterial disease treatment. Stryker CEO Kevin Lobo said the deal advances the company's vision to build a comprehensive peripheral vascular platform addressing significant clinical needs. IVL technology is experiencing strong growth as physicians increasingly adopt it for calcium modification in complex cardiovascular procedures. The transaction remains subject to customary closing conditions.
Stryker has raised $120 million in a Series C round led by Ribbit Capital, valuing the medical technology company at $1.45 billion. The funding comes despite shares declining 7.6% over the past six months, outperforming the industry's 19.7% drop. The company delivered 11% organic sales growth in Q4 2025 and 10.3% for the full year, marking its fourth consecutive year of double-digit growth. Performance was broad-based across its Orthopaedics, MedSurg and Neurotechnology segments, driven by strong procedural volumes and favourable demographics. Stryker achieved over 100 basis points of operating margin expansion for the second consecutive year despite tariff pressures. The company enters 2026 with a robust capital equipment backlog, though rising interest costs and tariffs present near-term challenges. Analysts maintain a Hold rating on the stock.
Stryker shares fell 9% to $339 following a destructive cyberattack by Iranian-linked group Handala that wiped over 200,000 systems and disrupted manufacturing and shipping operations across 56,000 employees in 61 countries. The medical technology company confirmed disruptions to order processing but stated there was no indication of ransomware. Unlike typical ransomware attacks, this wiper attack permanently deleted data rather than holding it for ransom, complicating recovery efforts. The incident threatens Stryker's 8% to 9.5% organic growth guidance for 2026 if operations fail to normalise quickly. Stryker generated $25 billion in revenue in 2025 with $4.283 billion in free cash flow and holds $4 billion in cash. Analysts maintain a consensus price target of $424.89 with 22 buy ratings and no sell ratings among 30 covering analysts.
Stryker reported Q4 revenues of $7.17 billion, up 11.4% year-over-year and exceeding analyst expectations by 0.8%. The medical device manufacturer, which impacts over 150 million patients annually through its orthopaedics, surgical tools, neurotechnology and patient care solutions, delivered what CEO Kevin Lobo called "an outstanding finish to 2025". The company achieved double-digit sales and adjusted earnings per share growth for both the quarter and full year, whilst expanding adjusted operating margin by at least 100 basis points for the second consecutive year. Across the medical devices and supplies sector, the six diversified stocks tracked reported mixed Q4 results. As a group, revenues beat consensus estimates by 1.9%, though share prices have declined an average of 5.1% since the latest earnings announcements.